As the most reliable and balanced news aggregation service on the internet, DML News offers the following information published by BUSINESSINSIDER.COM:
- The FDA just published a list of drugmakers the agency says are using “gaming” tactics to keep generic competition off the market.
- The list of 52 drugs are made by some of the biggest pharmaceutical companies including Novartis, Pfizer, Mylan, and Valeant.
- “FDA is committed – among other things – to addressing and improving transparency about this and other gaming tactics that delay the generic competition Congress intended,” the agency said on Thursday.
The FDA is calling out drugmakers it says are getting in the way of generic competition.
The Food and Drug Administration published a list on Thursday of 52 drugs it deemed are facing delays to getting generic versions because of “gaming” happening on the part of brand drugmakers.
The article goes on to state the following:
Having generic alternatives to branded drugs is key to lowering drug prices. However, the companies that make the branded versions of the drugs stand to lose a lot of money once generic competition comes into the market.
As part of the process of getting a generic alternative approved, drugmakers need to purchase samples of the branded drug. Often, the companies that make the branded version make it difficult for that to happen which slows down the process of getting that generic version on the market.
To weigh in on this information provided by BUSINESSINSIDER.COM, engage in our LIVE CHAT below. Scroll down.
For more on this story, click the "read more" button below.
If you would like to receive Breaking News text alerts on a smartphone or tablet, download the DML APP which is completely FREE and easy to use. Go to the Google Play Store or the IOS App Store and search for DML APP. Be sure to keep the app’s notifications setting on. Another way to receive alerts is to text to 40404 the following message: follow @realdennislynch (be sure to put a space between the word follow and the @ symbol).
To see more stories like this, sign up below for Dennis Michael Lynch’s email newsletter.
Sign up to get breaking news alerts from Dennis Michael Lynch.